START

The Synaptic Therapy Alzheimer’s Research Trial (START) is a national study funded by the National Institute on Aging (NIA) of the National Institutes of Health (NIH).

Through the START study, researchers seek to learn if a new drug treatment taken orally, called CT1812, can safely slow memory loss caused by Alzheimer’s disease.

In the START study, the investigational treatment, called CT1812 which is taken as an oral capsule, is being evaluated for possible benefit in slowing down memory loss caused by Alzheimer’s disease.

Study participants:

Make an 18-month commitment to participate in the study.
Attend in-person visits for medical assessments and procedures.
Have a close friend or relative, who sees and talks with the participant every week, who can serve as their study partner.
Receive $100 per visit they attend for their time.

For more study details, please visit the START study website.

Participation Eligibility

You may be eligible if you:

Are ages 50 to 85.
Have a diagnosis of either mild cognitive impairment (MCI) due to Alzheimer’s disease or mild Alzheimer’s disease dementia.
Are able and willing to agree to an 18-month commitment to participate in the study.
Are able and willing to take the investigational treatment or placebo daily in the form of oral capsules.
Have a study partner. A study partner is one or more people that have frequent contact with the study participant and agree to take part in information-based assessments in-person and by telephone.

Contact the study coordinator below to find out if you are eligible to enroll in the START Study.